What Are the Biomarkers for Immunotherapy in SCLC?

What Are the Biomarkers for Immunotherapy in SCLC?

Small-cell lung cancer (SCLC) is an aggressive malignancy that exhibits a rapid doubling time, a high growth fraction, and the early development of widespread metastases. The addition of immune checkpoint inhibitors to first-line chemotherapy represents the first significant improvement of systemic...

Full description

Bibliographic Details
Main Authors: Vito Longo, Annamaria Catino, Michele Montrone, Pamela Pizzutilo, Tiziana Annese, Francesco Pesola, Ilaria Marech, Sandro Cassiano, Domenico Ribatti, Domenico Galetta
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:International Journal of Molecular Sciences
Subjects:
SCLC
biomarkers
programmed death ligand 1
tumour mutational burden
tumour microenvironment
serum anti-neuronal nuclear antibodies
Online Access:https://www.mdpi.com/1422-0067/22/20/11123

Internet

https://www.mdpi.com/1422-0067/22/20/11123

Similar Items